COVID-19 trials registries data warehouse

 Return to trial list

Trial - NCT04412057


Column Value
Trial registration number NCT04412057
Full text link
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov

First author
Last imported at : March 4, 2021, 12:31 a.m.
Source : ClinicalTrials.gov

H. Jeffrey Wilkins, MD

Contact
Last imported at : March 4, 2021, 12:31 a.m.
Source : ClinicalTrials.gov

jwilkins@cerecor.com

Registration date
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov

2020-06-02

Recruitment status
Last imported at : March 4, 2021, 12:31 a.m.
Source : ClinicalTrials.gov

Completed

Study design
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov

RCT

Allocation
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov

Randomized

Design
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov

Parallel

Masking
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov

Blind label

Center
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov

multi-center

Study aim
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov

Treatment

Inclusion criteria
Last imported at : March 27, 2022, 4 p.m.
Source : ClinicalTrials.gov

inclusion criteria: subject/legally authorized representative (lar) is able to understand and provide written informed consent, and assent (as applicable) to participate in this study. subject is ≥18 years of age at the time of informed consent and assent (as applicable). subject is male or non-pregnant, non-lactating female, who if of childbearing potential agrees to comply with any applicable contraceptive requirements if. discharged from the hospital prior to completing the study. subject has a diagnosis of covid-19 infection through an approved testing method. subject has been hospitalized due to clinical diagnosis of pneumonia with acute lung injury defined as diffuse bilateral radiographic infiltrates with partial pressure of arterial oxygen/percentage of inspired oxygen (pao2/fio2) >100 and <300. subject's oxygen saturation at rest in ambient air <93%

Exclusion criteria
Last imported at : Nov. 16, 2021, 6:30 p.m.
Source : ClinicalTrials.gov

subject is intubated. subject is currently taking immunomodulators or anti-rejection drugs. subject has been administered an immunomodulating biologic drug within 60 days of baseline. subject is in septic shock defined as persistent hypotension requiring vasopressors to maintain mean arterial pressure (map) of 65 mm hg or higher and a serum lactate level greater than 2 mmol/l (18 mg/dl) despite adequate volume resuscitation. subject has received any live attenuated vaccine, such as varicella-zoster, oral polio, or rubella, within 3 months prior to the baseline visit.

Number of arms
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov

2

Funding
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov

Aevi Genomic Medicine, LLC, a Cerecor company

Inclusion age min
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov

18

Inclusion age max
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov

100

Countries
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov

United States

Type of patients
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov

Severe disease at enrollment

Severity scale
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov

6: Severe disease at enrollment

Total sample size
Last imported at : March 5, 2022, 9:30 p.m.
Source : ClinicalTrials.gov

88

primary outcome
Last imported at : March 27, 2022, 4 p.m.
Source : ClinicalTrials.gov

Number of Subjects Alive and Free of Respiratory Failure

Notes
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov

None

Phase
Last imported at : Feb. 25, 2021, 7:58 p.m.
Source : ClinicalTrials.gov

Phase 2

Arms
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov

[{"arm_notes": "", "treatment_id": 265, "treatment_name": "Cerc-002", "treatment_type": "Monoclonal antibodies", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}]